Professor

PATERSON David Leslie

Affiliation

  • NUS Saw Swee Hock School of Public Health (Joint)
  • NUS Yong Loo Lin School of Public Health (Joint)
  • Director, ADVANCE-ID
  • University of Queensland Faculty of Medicine (Honorary)

Research Areas

  • Clinical Trials
  • Antimicrobial Resistance (AMR)

Teaching Areas

  • Mentorship of Clinical Researchers

Academic/Professional Qualifications

  • MBBS (UQ): December 1988
  • Fellowship of the Royal Australasian College of Physicians: Advanced Training in Infectious Diseases: December 1995
  • Post-Graduate Diploma in Epidemiology and Biostatistics (University of Newcastle, Australia): 1996
  • Fellowship of the Royal College of Pathologists of Australasia (Clinical Microbiology): 2005
  • PhD (UQ): 2005

Awards/Honours

  • European Society for Clinical Microbiology and Infectious Diseases Fellow (2017)
  • Australian Academy of Health Medical Sciences Fellow: “Fellows of the Academy will have manifested their suitability by the exercise of outstanding leadership in the science of health medicine” (2015)
  • Faculty Researcher of the Year: University of Queensland, Faculty of Medicine (2015)
  • Bancroft Orator, Australian Medical Association (2013)
  • Achievement Award for top ranked NHMRC Practitioner Fellow (2010)
  • Frank Fenner Award for Advanced Research in Infectious Diseases (2008)
  • Elected, Academy of Master Educators, University of Pittsburgh School of Medicine (2006)
  • Irving S. Sigal Memorial Award for “Significant Research in Microbiology and Infectious Diseases”: American Society for Microbiology Young Investigator of the Year Award (2000)

Administrative Leadership

  • Director, University of Queensland Centre for Clinical Research, Brisbane, Australia (2017-2022)

Professional/Consulting Activities

  • Member, Scientific Advisory Board, AMR Action Fund

Selected Publications

  • Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 Sep 11;320(10):984-994. Impact Factor 157

Media Coverage

Back to Faculty Directory